8-K: Evolution Global SPAC raises $240M in IPO

Evolution Global Acquisition Corp completes a $240 million SPAC IPO, fully exercises the over-allotment, funds its trust, and discloses private warrant sales and key SPAC terms.

Summary

• Closed the IPO on November 12, 2025, selling 24,000,000 units at $10.00 each (including full 3,000,000-unit over-allotment), for $240,000,000 in gross proceeds.
• Deposited $240,000,000 ($10.00 per public share) into a U.S. trust account; funds initially held in cash and to be invested in short-term U.S. Treasuries or qualifying money market funds.
• Completed a concurrent private placement of 6,800,000 warrants at $1.00 each for $6,800,000 in gross proceeds (Sponsor 4,400,000; Cohen & Co. 2,400,000, including Clear Street participation).
• Outstanding warrants total 18,800,000 (12,000,000 public; 6,800,000 private), each exercisable at $11.50 for one Class A share; callable if shares trade at or above $18.00 for 20 of 30 trading days post-De-SPAC.
• Transaction costs totaled $15,036,813, including $4,320,000 cash underwriting fee (net of $480,000 reimbursement), $9,600,000 deferred underwriting fee, and $1,116,813 of other costs.
• Balance sheet (as of November 12, 2025): cash outside trust $1,234,679; working capital $1,180,269; deferred underwriting fee $9,600,000; accrued offering costs $154,940; accumulated deficit $(8,349,730).
• Founder Shares outstanding total 8,000,000 Class B shares (25% of post-IPO shares, on an as-converted basis); over-allotment exercise eliminated the 1,000,000-share forfeiture condition.
• Officers and directors received membership interests equivalent to 1,958,333 Founder Shares on November 10, 2025 (fair value $5,032,916, expensed immediately).
• Completion window to consummate a business combination is 24 months from the IPO closing; public shareholders have redemption rights at approximately $10.00 per share plus pro rata interest.
• Underwriters’ deferred fee of $9,600,000 is payable only upon completing a business combination; otherwise waived.
• Related party items: Sponsor promissory note of $241,107 fully repaid at IPO close; $803 due from Sponsor; $480,000 advisory fee paid to Evolution Capital Pty Ltd (managed by CEO).
• Audited balance sheet issued November 18, 2025 by WithumSmith+Brown, PC; tickers listed on Nasdaq: EVOXU (units), EVOX (Class A), EVOXW (warrants).

Sentiment

Score: 7

Explanation: Successful IPO with full over-allotment and fully funded trust is positive; however, a relatively high founder promote and sizable deferred underwriting fee imply above-average dilution risk.

Positives

• IPO fully subscribed with full over-allotment, raising $240,000,000 and funding the trust at $10.00 per public share.
• Additional $6,800,000 from private placement warrants provides incremental liquidity for expenses pre-business combination.
• Strong cash outside trust of $1,234,679 and working capital of $1,180,269 immediately post-IPO.
• Underwriters’ $9,600,000 deferred compensation is contingent on closing a business combination, aligning costs with transaction success.
• Sponsor backstop: agreement to be liable for certain third-party claims that would otherwise reduce the trust below $10.00 per public share (subject to specified exemptions).
• Audited balance sheet available promptly (issued November 18, 2025), supporting transparency and readiness.

Negatives

• Founder promote at 8,000,000 Class B shares equals 25% of post-IPO shares (higher than the 20% seen in many SPACs), implying greater potential dilution.
• Large deferred underwriting fee of $9,600,000 increases effective transaction costs upon completing a deal.
• Accumulated deficit of $(8,349,730) driven by offering costs and $5,032,916 founder-share-based compensation expense recorded pre-IPO.
• Total transaction costs of $15,036,813 reduce net proceeds available outside the trust.
• Warrants (18,800,000 outstanding) introduce additional future dilution if a business combination succeeds and the stock performs.

Risks

• Ability to consummate a business combination within 24 months is uncertain; failure would trigger liquidation and redemption of public shares.
• Macroeconomic and market headwinds (inflation, interest rate fluctuations, financial market downturns, supply chain disruptions, declines in consumer confidence) may impede identifying and closing a deal.
• Geopolitical instability, including military conflicts in Ukraine and the Middle East, could adversely affect transaction timing and targets.
• Regulatory changes could impact SPAC structures, disclosure, accounting, or deal feasibility.
• Third-party claims could reduce trust funds; Sponsor indemnity excludes claims from parties that sign waivers and underwriter indemnity claims.
• Concentration of cash balances above FDIC limits poses counterparty risk to bank deposits outside the trust.

Future Outlook

Proceeds are intended to fund a business combination within 24 months of the IPO closing. Public shareholders will have redemption rights at approximately $10.00 per share plus interest upon a proposed transaction. If no deal is completed within the completion window (absent a shareholder-approved extension), funds in the trust will be returned to public shareholders and the SPAC will liquidate.

Management Comments

• Intends to invest trust funds in short-duration U.S. government treasuries or qualifying money market funds until a business combination or liquidation.
• Plans to provide public shareholders the right to redeem their shares for a pro rata portion of the trust upon the completion of a business combination or in a tender offer.
• Holds broad discretion over target selection but must acquire one or more businesses with an aggregate fair market value of at least 80% of the value of the trust (excluding deferred underwriting commissions and taxes).
• Affirms a 24-month completion window to consummate a business combination, subject to potential shareholder-approved extension.

Industry Context

Terms align with recent SPAC structures, including $10.00 units, half-warrants, a 24-month completion window, and sizable deferred underwriting fees. The SPAC market has faced higher redemption rates and regulatory scrutiny, making target selection and deal structure critical for successful de-SPAC outcomes.

Comparison to Industry Standards

• Deal size: $240M is within the common $200–300M range for Nasdaq-listed SPACs.
• Warrant coverage: Half-warrant per unit and $11.50 strike are standard; 18.8M total warrants indicate typical dilution potential.
• Promote: 25% Founder Shares (8.0M B vs. 24.0M A) is higher than the 20% promote seen in many SPACs, implying greater dilution than peers like average 2021–2023 SPAC cohorts.
• Fees: Upfront underwriting fee effectively 2% and deferred 4% (total ~6%) is slightly above the 5.5% often observed (2% upfront, 3.5% deferred) in comparable SPACs.
• Completion window: 24 months is standard; aligns with peers such as SPACs sponsored by established sponsors on Nasdaq.
• Trust funding: $10.00 per share fully funded at IPO aligns with market practice aimed at redemption protection.

Corporate Governance

Related Party Transactions

• Sponsor purchased 4,400,000 private placement warrants at $1.00 each ($4,400,000).
• Advisory fee of $480,000 paid to Evolution Capital Pty Ltd (managed by CEO) at IPO close for management consulting and corporate advisory services.
• Sponsor promissory note for IPO costs ($241,107) repaid at IPO closing; $803 due from Sponsor outstanding at balance sheet date.
• Officers and directors granted membership interests equivalent to 1,958,333 Founder Shares on November 10, 2025 (aggregate fair value $5,032,916 expensed).

Stakeholder Impact

• Public shareholders receive redemption protection at approximately $10.00 per share plus any pro rata trust interest.
• Underwriters’ deferred fee is contingent on deal completion, reducing cash leakage if no transaction closes.
• Sponsor indemnity for certain third-party claims helps preserve trust value, benefiting public shareholders.
• Founder promote (25%) and outstanding warrants increase potential dilution for public shareholders post-de-SPAC.
• Employees and target-company stakeholders (future) may be impacted by transaction structure and dilution at closing.
• Creditors and service providers face reliance on Sponsor indemnity and waivers related to trust funds.

Next Steps

• Identify and negotiate a business combination within 24 months of the IPO closing.
• File and make effective a registration statement for warrant exercises within 60 business days after completing a business combination.
• Provide redemption mechanism (shareholder vote or tender offer) for public shareholders at the time of a proposed business combination.
• If needed, seek shareholder approval for any extension to the completion window, offering redemptions in connection with any such extension.

Key Dates

Keywords

SPAC, Initial Public Offering, Evolution Global Acquisition Corp, EVOX, EVOXU, EVOXW, trust account, redeemable shares, warrants, deferred underwriting, Founder Shares, business combination, Cohen & Company Capital Markets, Clear Street, WithumSmith+Brown, Cayman Islands